Insider Trading Alert - ACE, EVLV And MNTA Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 27, 2015, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $945.00 to $3,999,999.00.

Highlighted Stocks Traded by Insiders:

ACE (ACE) - FREE Research Report

Menikoff Peter, who is Director at ACE, sold 1,906 shares at $108.30 on May 27, 2015. Following this transaction, the Director owned 57,548 shares meaning that the stake was reduced by 3.21% with the 1,906-share transaction.

The shares most recently traded at $106.81, down $1.49, or 1.4% since the insider transaction. Historical insider transactions for ACE go as follows:

  • 4-Week # shares sold: 17,500
  • 12-Week # shares sold: 17,500
  • 24-Week # shares sold: 17,500

The average volume for ACE has been 1.3 million shares per day over the past 30 days. ACE has a market cap of $34.9 billion and is part of the financial sector and insurance industry. Shares are down 6.55% year-to-date as of the close of trading on Wednesday.

ACE Limited, through its subsidiaries, provides a range of property and casualty insurance and reinsurance products worldwide. The stock currently has a dividend yield of 2.51%. The company has a P/E ratio of 12.8. Currently, there are 9 analysts who rate ACE a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACE - FREE

TheStreet Quant Ratings rates ACE as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full ACE Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

EVINE Live (EVLV) - FREE Research Report

Bozek Mark C, who is Chief Executive Officer at EVINE Live, bought 13,350 shares at $3.84 on May 27, 2015. Following this transaction, the Chief Executive Officer owned 27,350 shares meaning that the stake was boosted by 95.36% with the 13,350-share transaction.

The shares most recently traded at $3.59, down $0.25, or 6.96% since the insider transaction. Historical insider transactions for EVINE Live go as follows:

  • 4-Week # shares bought: 4,000
  • 4-Week # shares sold: 49,057
  • 12-Week # shares bought: 5,500
  • 12-Week # shares sold: 173,718
  • 24-Week # shares bought: 5,500
  • 24-Week # shares sold: 173,718

The average volume for EVINE Live has been 336,300 shares per day over the past 30 days. EVINE Live has a market cap of $205.1 million and is part of the services sector and retail industry. Shares are down 47.95% year-to-date as of the close of trading on Wednesday.

EVINE Live Inc. operates as a digital commerce company in the United States. Currently, there are 6 analysts who rate EVINE Live a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EVLV - FREE

TheStreet Quant Ratings rates EVINE Live as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full EVINE Live Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Momenta Pharmaceuticals (MNTA) - FREE Research Report

Bishop John E, who is Senior VP, Pharmaceutical Scie at Momenta Pharmaceuticals, sold 254 shares at $19.80 on May 27, 2015. Following this transaction, the Senior VP, Pharmaceutical Scie owned 110,380 shares meaning that the stake was reduced by 0.23% with the 254-share transaction.

The shares most recently traded at $19.16, down $0.64, or 3.34% since the insider transaction. Historical insider transactions for Momenta Pharmaceuticals go as follows:

  • 4-Week # shares sold: 10,771
  • 12-Week # shares sold: 136,849
  • 24-Week # shares sold: 166,955

The average volume for Momenta Pharmaceuticals has been 1.0 million shares per day over the past 30 days. Momenta Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are up 62.87% year-to-date as of the close of trading on Wednesday.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. Currently, there are 4 analysts who rate Momenta Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNTA - FREE

TheStreet Quant Ratings rates Momenta Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Momenta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

The Future of Cars, Nvidia, CBS: Three Keys to Your Investing Day

The Future of Cars, Nvidia, CBS: Three Keys to Your Investing Day

Kimberly-Clark Tops Q3 Earnings Despite Currency Headwinds; CEO Falk Steps Down

Kimberly-Clark Tops Q3 Earnings Despite Currency Headwinds; CEO Falk Steps Down

It Is Better to Be Late Than Early When It Comes to Stock Market Turns

It Is Better to Be Late Than Early When It Comes to Stock Market Turns

Facebook, Fiat Chrysler, China Stocks and CBS - 5 Things You Must Know

Facebook, Fiat Chrysler, China Stocks and CBS - 5 Things You Must Know

How to Play Ford, Despite Its Lousy Chart: Market Recon

How to Play Ford, Despite Its Lousy Chart: Market Recon